Intervention Review

You have free access to this content

Interventions for preventing critical illness polyneuropathy and critical illness myopathy

  1. Greet Hermans1,
  2. Bernard De Jonghe2,
  3. Frans Bruyninckx3,
  4. Greet Van den Berghe4,*

Editorial Group: Cochrane Neuromuscular Group

Published Online: 30 JAN 2014

Assessed as up-to-date: 4 OCT 2011

DOI: 10.1002/14651858.CD006832.pub3


How to Cite

Hermans G, De Jonghe B, Bruyninckx F, Van den Berghe G. Interventions for preventing critical illness polyneuropathy and critical illness myopathy. Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No.: CD006832. DOI: 10.1002/14651858.CD006832.pub3.

Author Information

  1. 1

    KU Leuven, Department of Cellular and Molecular Medicine, Leuven, Belgium

  2. 2

    Centre Hospitalier de Poissy-Saint-Germain, Réanimation Médico-Chirurgicale, Poissy, France

  3. 3

    KU Leuven, University Hospitals, Physical Medicine and Rehabilitation, Leuven, Belgium

  4. 4

    KU Leuven, University Hospitals, Department of Intensive Care Medicine, Leuven, Belgium

*Greet Van den Berghe, Department of Intensive Care Medicine, KU Leuven, University Hospitals, Herestraat 49,3000, Leuven, Belgium. Greta.vandenberghe@med.kuleuven.be.

Publication History

  1. Publication Status: New search for studies and content updated (conclusions changed)
  2. Published Online: 30 JAN 2014

SEARCH

[Figure 1]
Figure 1. Presumed pathophysiological mechanisms and their interactions involved in the development of CIP/CIM. Dark shaded area indicates events taking place in the nerves, light shaded area indicates events taking place in the muscle. (Additional abbreviations: ROS, reactive oxygen species; SR, sarcoplasmic reticulum).
[Figure 2]
Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Red (-) = high risk of bias; green (+) = low risk of bias; yellow (?) = unclear risk of bias (not shown).
[Figure 3]
Figure 3. Forest plot of comparison: 1 Intensive insulin therapy (IIT) versus conventional insulin therapy (CIT), outcome: 1.1 Occurrence of CIP/CIM.
[Figure 4]
Figure 4. Forest plot of comparison: 2 Corticosteroids versus placebo, outcome: 2.1 Occurrence of CIP/CIM.
[Figure 5]
Figure 5. Forest plot of comparison: 6 EarIy physical therapy versus control, outcome: 6.1 Occurence of CIP/CIM.
[Figure 6]
Figure 6. Forest plot of comparison: 4 Elecrical magnetic stimulation versus control, outcome: 4.1 Occurrence of CIP/CIM.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Intensive insulin therapy (IIT) versus conventional insulin therapy (CIT), Outcome 1 Occurrence of CIP/CIM.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Intensive insulin therapy (IIT) versus conventional insulin therapy (CIT), Outcome 2 Duration of mechanical ventilation.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Intensive insulin therapy (IIT) versus conventional insulin therapy (CIT), Outcome 3 Duration of ICU stay.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Intensive insulin therapy (IIT) versus conventional insulin therapy (CIT), Outcome 4 Death.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Intensive insulin therapy (IIT) versus conventional insulin therapy (CIT), Outcome 5 Serious adverse events.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Corticosteroids versus placebo, Outcome 1 Occurrence of CIP/CIM.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Corticosteroids versus placebo, Outcome 2 Death.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Corticosteroids versus placebo, Outcome 3 Serious adverse events (dichotomous data).
[Analysis 2.4]
Analysis 2.4. Comparison 2 Corticosteroids versus placebo, Outcome 4 Serious adverse events (continuous data).
[Analysis 3.1]
Analysis 3.1. Comparison 3 Early physical therapy versus control, Outcome 1 Occurrence of CIP/CIM.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Early physical therapy versus control, Outcome 2 Serious adverse events.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Electrical muscle stimulation versus control, Outcome 1 Occurrence of CIP/CIM.